DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1546 review of the published evidence. J Antimicrob Chemother,
2006, 58:273–280.
Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of
high-dose intravenous daptomycin treatment: Three-year
cumulative experience in a clinical program. Clin Infect Dis,
2009, 49:177–180.
Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus
standard therapy for bacteremia and endocarditis caused
by Staphylococcus aureus. N Engl J Med, 2006, 355:653–665.
Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended
dosing of vancomycin for children with invasive
methicillin-resistant staphylococcus aureus infections is inadequate.
Pediatr Infect Dis, 2009, 28:398–402.
Fuller DG, Duke T, Shann R, Curtis N. Antibiotic treatment for
bacterial meningitis in children in developing countries. Ann
Trop Paediatr, 2003, 23:233–253.
Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested
against 11808 bacterial pathogens recently collected from US
medical centers. Diagn Microbiol Infect Dis, 2008, 60:421–427.
Garey KW, Amsden GW. Intravenous azithromycin. Ann
Pharmacother, 1999, 33:218–228.
Garrett DO, Jochimsen E, Murfitt K, et al. The emergence of
decreased susceptibility to vancomycin in Staphylococcus epidermidis.
Infect Control Hosp Epidemiol, 1999, 20:167–170.
Gatti G, Malena M, Casazza R, et al. Penetration of clindamycin
and its metabolite N-demethylclindamycin into cerebrospinal
fluid following intravenous infusion of clindamycin phosphate
in patients with AIDS. Antimicrob Agents Chemother, 1998,
42:3014–3017.
Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of
the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin,
daptomycin, linezolid, and four comparator agents
against anaerobic gram-positive species and Corynebacterium
spp. Antimicrob Agents Chemother, 2004, 48:2149–2152.
Halperin SA, Bortolussi R, Langley JM, et al. Seven days of
erythromycin estolate is as effective as fourteen days for the
treatment of Bordetella pertussis infections. Pediatrics, 1997,
100:65–71.
Hamel JC, Stapert D, Moerman JK, Ford CW. Linezolid, critical
characteristics. Infection, 2000, 28:60–64.
Hedberg M, Nord CE. Antimicrobial susceptibility of
Bacteroides fragilis group isolates in Europe. Clin Microbiol
Infect, 2003, 9:475–488.
Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese
hospitals of strains of Staphylococcus aureus heterogeneously
resistant to vancomycin. Lancet, 1997, 350:1670–1673.
Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of
antimicrobial resistance in Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis in the
SENTRY Antimicrobial Surveillance Program, 1997–1999.
Clin Infect Dis, 2001, 32:S81–S93.
Howden BP, Ward PB, Charles PG, et al. Treatment outcomes
for serious infections caused by methicillin-resistant
Staphylococcus aureus with reduced vancomycin susceptibility.
Clin Infect Dis, 2004, 38:521–528.
Jevitt LA, Smith AJ, Williams PP, et al. In vitro activities of
Daptomycin, Linezolid, and Quinupristin-Dalfopristin
against a challenge panel of Staphylococci and Enterococci,
including vancomycin-intermediate Staphylococcus aureus
and vancomycin-resistant Enterococcus faecium. Microb
Drug Resist, 2003, 9:389–393.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al.
Surgical site infections in orthopedic surgery: The effect of
mupirocin nasal ointment in a double-blind, randomized,
placebo-controlled study. Clin Infect Dis, 2002, 35:353–358.
Kovacs JA, Masur H. Prophylaxis against opportunistic infections
in patients with human immunodeficiency virus infection.
N Engl J Med, 2000, 342:1416–1429.
Laupland KB, Conly JM. Treatment of Staphylococcus aureus
colonization and prophylaxis for infection with topical
intranasal mupirocin: An evidence-based review. Clin Infect
Dis, 2003, 37:933–938.
Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared
with penicillin for the treatment of anaerobic lung
abscess. Ann Intern Med, 1983, 98:466–471.
Lewis JS, Jorgensen JH. Inducible clindamycin resistance in
Staphylococci: Should clinicians and microbiologists be concerned?
Clin Infect Dis, 2005, 40:280–285.
Lina G, Quaglia A, Reverdy ME, et al. Distribution of genes
encoding resistance to macrolides, lincosamides, and streptogramins
among staphylococci. Antimicrob Agents Chemother,
1999, 43:1062–1066.
Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin
for the treatment of serious infection due to antimicrobialresistant
Pseudomonas aeruginosa. Clin Infect Dis, 2003,
37:154–160.
Lodise TP, Patel N, Lomaestro BM, et al. Relationship between
initial vancomycin concentration-time profile and nephrotoxicity
in hospitalized patients. Clin Infect Dis, 2009, 49:507–514.
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases
Society of America/American Thoracic Society consensus
guidelines on the management of community-acquired pneumonia
in adults. Clin Infect Dis, 2007, 44(suppl): S27–S72.
Masters EJ, Olson GS, Weiner SJ, et al. Rocky Mountain spotted
fever: A clinician’s dilemma. Arch Intern Med, 2003,
163:769–774.
Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and
safety of quinupristin/dalfopristin for the treatment of infections
caused by vancomycin-resistant Enterococcus faecium.
J Antimicrob Chemother, 1999, 44:251–261.
Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ.
Pharmacodynamics of vancomycin and other antimicrobials
in patients with Staphylococcus aureus lower respiratory tract
infections. Clin Pharmacokinet, 2004, 43:925–942.
Moore MR, Perdreau-Remington F, Chambers HF, et al.
Vancomycin treatment failure associated with heterogeneous
vancomycin-intermediate Staphylococcus aureus in a patient
with endocarditis and in the rabbit model of endocarditis.
Antimicrob Agents Chemother, 2003, 47:1262–1266.
Nakajima Y. Mechanisms of bacterial resistance to macrolide
antibiotics. J Infect Chemother, 1999, 5:61–74.
Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and
optic neuropathy, lactic acidosis, and serotonin syndrome.
Pharmacotherapy, 2007, 27:1189–1197.
Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized
patients with complicated gram-positive skin and
skin structure infections: Two randomized, multicentre studies
of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin.
Synercid Skin and Skin Structure Infection Group.
J Antimicrob Chemother, 1999, 44:263–273.
Nilius AM, Ma Z. Ketolides: The future of the macrolides? Curr
Opin Pharmacol, 2002, 2:493–500.